Faze Medicines
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Faze researched small-molecule medicines targeting biomolecular condensates, initially for ALS and later for cancer.
02 / Faze Medicines FAILURE REASONS
Failure reasons
Investor Third Rock said scientific progress did not meet its threshold for further investment. Management recommended ending the business, and the board supported that decision; the programs had not reached human clinical testing.
03 / EVENT HISTORY
Events in the structured record
- Research company launched
The company launched in December to develop medicines based on condensate biology.
- Development and business ended
In November an investor confirmed the decision to close following insufficient scientific progress.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Drug programs remained in early research
- 02
Progress did not meet the investment threshold
- 03
Management and board chose wind-down
- 04
Research business closed